Show simple item record

dc.contributor.authorWeaver, Andrew
dc.contributor.authorRyder, W David J
dc.contributor.authorCrowther, Derek
dc.contributor.authorDexter, T Michael
dc.contributor.authorTesta, Nydia G
dc.date.accessioned2010-04-06T09:58:01Z
dc.date.available2010-04-06T09:58:01Z
dc.date.issued1996-11-01
dc.identifier.citationIncreased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. 1996, 88 (9):3323-8 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid8896396
dc.identifier.urihttp://hdl.handle.net/10541/95634
dc.description.abstractLong-term culture-initiating cells (LTC-IC) are arguably the most primitive human hematopoietic cells detectable by in vitro functional assays. We have investigated the mobilization of these cells into the blood of patients with ovarian carcinoma randomized to receive granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg) plus different doses of stem cell factor (SCF; c-kit ligand) after chemotherapy or G-CSF alone after chemotherapy. We have shown a significant SCF dose response for the mobilization of LTC-IC, with a 5.8-fold increase in LTC-IC mobilization in those patients receiving chemotherapy, G-CSF, and 20 micrograms/kg of SCF, the highest dose used, compared with the patients receiving chemotherapy and G-CSF alone. We have shown a threefold increase in CD34+ cells and up to a 64-fold increase in CD34+/33- cells was seen in patients treated with chemotherapy, G-CSF, and 20 micrograms/kg of SCF compared with those patients treated with chemotherapy and G-CSF alone. However, significant numbers of CD34+/38- cells were only found in the patients receiving 20 micrograms/kg of SCF as part of their mobilization regimen. Patients receiving chemotherapy plus G-CSF and SCF have enhanced mobilization of primitive cells and of the more committed progenitor cells compared with those patients receiving chemotherapy followed by G-CSF alone.
dc.language.isoenen
dc.subjectHaematopoietic Stem Cellsen
dc.subjectOvarian Canceren
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBlood Component Removal
dc.subject.meshCarcinoma
dc.subject.meshCell Count
dc.subject.meshClone Cells
dc.subject.meshCohort Studies
dc.subject.meshCyclophosphamide
dc.subject.meshFemale
dc.subject.meshGranulocyte Colony-Stimulating Factor
dc.subject.meshHematopoietic Stem Cells
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshMesna
dc.subject.meshMiddle Aged
dc.subject.meshOvarian Neoplasms
dc.subject.meshRecombinant Proteins
dc.subject.meshStem Cell Factor
dc.subject.meshTime Factors
dc.titleIncreased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Experimental Haematology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBlooden
html.description.abstractLong-term culture-initiating cells (LTC-IC) are arguably the most primitive human hematopoietic cells detectable by in vitro functional assays. We have investigated the mobilization of these cells into the blood of patients with ovarian carcinoma randomized to receive granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg) plus different doses of stem cell factor (SCF; c-kit ligand) after chemotherapy or G-CSF alone after chemotherapy. We have shown a significant SCF dose response for the mobilization of LTC-IC, with a 5.8-fold increase in LTC-IC mobilization in those patients receiving chemotherapy, G-CSF, and 20 micrograms/kg of SCF, the highest dose used, compared with the patients receiving chemotherapy and G-CSF alone. We have shown a threefold increase in CD34+ cells and up to a 64-fold increase in CD34+/33- cells was seen in patients treated with chemotherapy, G-CSF, and 20 micrograms/kg of SCF compared with those patients treated with chemotherapy and G-CSF alone. However, significant numbers of CD34+/38- cells were only found in the patients receiving 20 micrograms/kg of SCF as part of their mobilization regimen. Patients receiving chemotherapy plus G-CSF and SCF have enhanced mobilization of primitive cells and of the more committed progenitor cells compared with those patients receiving chemotherapy followed by G-CSF alone.


This item appears in the following Collection(s)

Show simple item record